A prospective study analyzing efficacy and safety of polymeric micelle paclitaxel (pm-Pac) plus tislelizumab and carboplatin for first-line treatment of patients with advanced squamous non-small-cell lung cancer
Latest Information Update: 08 Jul 2023
Price :
$35 *
At a glance
- Drugs Tislelizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Jul 2023 New trial record
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology